NCT07396558Recruiting
Intermittent Erector Spinae Plane Block Via Subcutaneous Port for Cancer Pain
Efficacy of Intermittent Erector Spinae Plane Block Via Subcutaneous Port for Cancer-Related Pain in Patients With Lung Cancer
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
Cancer-related pain is a common and challenging problem in patients with lung cancer, often requiring long-term pain management. Conventional pain treatments, including systemic medications, may not provide adequate relief or may cause significant side effects. The erector spinae plane (ESP) block is a regional anesthesia technique that can help reduce pain by delivering local anesthetic near the nerves supplying the chest wall. This study aims to evaluate the effectiveness and safety of intermittent ESP block administered through a subcutaneous port for controlling cancer-related pain in patients with lung cancer. Eligible patients with lung cancer and moderate to severe pain will receive intermittent ESP block injections via a subcutaneous port as part of their pain management plan. Pain intensity, analgesic requirements, and potential side effects will be assessed over time. The results of this study may help determine whether intermittent ESP block via a subcutaneous port is a useful and feasible option for improving pain control and quality of life in patients with lung cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- First submitted
- 1 Feb 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- Hanoi Medical University
- Diseases
- Lung cancer
- NCT number
- NCT07396558
What you commit to
- Study type: Interventional
- Planned participants: 180
- From 1 Mar 2026 to the primary completion date, 1 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Chest pain with radiation to the upper extremities, neck, or shoulder, suggestive of non-localized thoracic pain.
Other illness
- Severe hepatic or renal dysfunction, or severe heart failure (New York Heart Association class III-IV).
- Local infection at the injection or port placement site, or uncontrolled systemic infection.
- Known allergy to amide-type local anesthetics or other contraindications to regional anesthesia.
- Severe cognitive impairment, altered consciousness, or inability to cooperate with post-intervention monitoring.
Lab values
- Severe coagulation disorders, defined as:
- International normalized ratio (INR) \> 1.5
- Activated partial thromboplastin time (aPTT) \> 40 seconds
- Fibrinogen \< 1.5 g/L
- Platelet count \< 50 × 10⁹/L.
Other
- Severe cachexia or insufficient subcutaneous tissue that does not allow safe coverage of the subcutaneous port.
- Lack of adequate caregiver support for home-based follow-up after discharge or inability to coordinate follow-up with local healthcare facilities.
Who the study is looking for
- Adult patients diagnosed with advanced-stage lung cancer who are currently receiving palliative care only.
- Presence of chronic cancer-related chest pain lasting longer than 1 month, localized to the thoracic region due to chest wall invasion, pleural involvement, or bone metastases.
- Performance status ≤ 3 according to the Eastern Cooperative Oncology Group (ECOG), allowing placement of a subcutaneous port and maintenance of local anesthetic administration.
- Inadequate pain control with conventional analgesic therapies or clinical indication for the addition of regional analgesia.
- Ability to understand the study procedures and provide written informed consent after receiving a full explanation of the intervention.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hanoi Medical University Coordinator of this site? Confirm its status | Hanoi | Vietnam | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.